Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
20.59
-0.41 (-1.95%)
At close: Sep 11, 2026, 4:00 PM EDT
20.68
+0.09 (0.44%)
After-hours: Sep 11, 2026, 7:46 PM EDT
Cullinan Therapeutics Market Cap
Cullinan Therapeutics has a market cap or net worth of $1.33 billion as of September 11, 2026. Its market cap has increased by 246.68% in one year.
Market Cap
1.33B
Enterprise Value
992.60M
1-Year Change
246.68%
Ranking
Category
Stock Price
$20.59
ChartMarket Cap Chart
Since the IPO on January 8, 2021, Cullinan Therapeutics's market cap has increased from $829.45M to $1.33B, an increase of 59.75%. That is a compound annual growth rate of 8.60%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 1.33B | 116.71% |
| Dec 31, 2025 | 611.44M | -13.79% |
| Dec 31, 2024 | 709.21M | 62.69% |
| Dec 29, 2023 | 435.93M | -9.73% |
| Dec 30, 2022 | 482.90M | -28.36% |
| Dec 31, 2021 | 674.05M | -18.74% |
| Jan 8, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| First Tracks Biotherapeutics | 1.41B |
| Ultragenyx Pharmaceutical | 1.41B |
| Omeros | 1.40B |
| Savara | 1.38B |
| Vor Biopharma | 1.37B |
| Maze Therapeutics | 1.37B |
| Replimune Group | 1.36B |
| Aktis Oncology | 1.34B |